University of Patras
Νευροπροστατευτική και αντιφλεγμονώδης δράση της συνθετικής μικρονευροτροφίνης BNN-20 στο μοντέλο προοδευτικής ντοπαμινεργικής νευροεκφύλισης μυός "weaver"
Abstract
dc:descriptionBNN-20 is a synthetic microneurotrophin, long-term administration (P1-P21) of which exerts potent neuroprotective effect on the “weaver” mouse, a genetic model of progressive, nigrostriatal dopaminergic degeneration. The present study provides evidence that BNN-20 fully protects the dopaminergic neurons even when administration begins at a late stage of dopaminergic degeneration (41% and 56%) simulating more accurately the one seen in human PD when the symptoms appear.Given that neuroinflammation plays a critical role in neurodegeneration in the “weaver” mouse, as well as in human Parkinson’s disease, the possibility of anti-neuroinflammatory mechanisms underlying the pharmacological action of BNN-20 is now investigated. The latter was shown to be microglia-mediated, at least in part. Indeed, BNN-20 induced a partial, but significant, reversal of microglia hyperactivation, observed in the “untreated” weaver mouse. Furthermore, BNN-20, causing a robust decrease of the neurotoxic (M1) microglia phenotype, it induced a shift in microglia polarization towards the neuroprotective (M2) phenotype, suggesting a possible beneficial shifting of microglia activity. This observation was further supported by morphometric measurements showing that BNN-20 significantly reduced the enlarged microglia cell somata in the Substantia Nigra of the “weaver” mouse. These results indicate robust anti-inflammatory action of BNN-20.Furthermore, BDNF levels, were severely reduced in the “weaver” mouse midbrain, as is the case with the midbrain of patients with Parkinson’s disease. Given the key role of BDNF in the survival of dopaminergic neurons, restoring its levels is seen as a potential therapeutic strategy. However, clinical use is limited by the fact that BDNF does not cross the blood-brain-barrier. Our results showed that short-term BNN-20 (P60-P74) administration, restored BDNF levels to normal. By intercrossing “weaver” and NGL (dual GFP/Luciferase–NFκB reporter mice –NFκB.GFP.Luc) mice, we were able to produce a new transgenic model, “weaver”/ NGL mice, whose somatic cells express the NFκB transgene. Using this new model and bioluminescence imaging, we have shown, in vivo, that ΒΝΝ-20 binds to TrkB and induces BDNF production, through TrkB-PI3K-Akt- NFκΒ and/or TrkB-ERK1/2-NFκΒ signaling pathway.Given that ΒΝΝ-20 crosses blood-brain-barrier, and is deprived of estrogen-related side effects, our results point ΒΝΝ-20 as a potential therapeutic to Parkinson’s disease.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Panagiotakopoulou, Vasiliki
- Παναγιωτακοπούλου, Βασιλική
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45366